The 4q12 amplicon in malignant peripheral nerve sheath tumors: Consequences on gene expression and implications for sunitinib treatment

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Zietsch, Jan ^a   Ziegenhagen, Nicolas ^a   Heppner, Frank L ^a   Reuss, David ^b   von Deimling, Andreas ^b   Holtkamp, Nikola ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; SUNITINIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRROLE DERIVATIVE; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN A;

AMPLICON; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMOSOME 14Q; CONTROLLED STUDY; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NERVE SHEATH TUMOR; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; NERVE SHEATH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955699525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011858     Document Type: Article

References (31)

1. von Deimling A, Krone W, Menon A (1995) Neurofibromatosis Type 1: Pathology, clinical features and molecular genetics. Brain Pathology 5: 153- 162.
2. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, et al. (2006) Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27: 664-671.
3. Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, et al. (2007) Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 9: 291-297.
4. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN (2005) Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 207: 224-231.
5. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, et al. (2005) Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 65: 8085-8089.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. (1998) Gainof- function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
7. Serra E, Rosenbaum T, Nadal M, Winner U, Ars E, et al. (2001) Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat Genet 28: 294-296.
8. Betsholtz C, Karlsson L, Lindahl P (2001) Developmental roles of plateletderived growth factors. Bioessays 23: 494-507.
9. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M (2002) Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol 197: 98-107.
10. Nakagawa Y, Yoshida A, Numoto K, Kunisada T, Wai D, et al. (2006) Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. Oncol Rep 15: 297-303.
11. Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39: 29-36.
12. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, et al. (1996) Association of loss of heterozygosity on chromosome 17p with high plateletderived growth factor alpha receptor expression in human malignant gliomas. Cancer Research 56: 164-171.
13. Shih AH, Holland EC (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232: 139-147.
14. Kuchenbauer F, Schoch C, Holler E, Haferlach T, Hiddemann W, et al. (2005) A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongen and multiple other molecular aberrations. Leukemia 19: 2366-2368.
15. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
16. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T (2003) Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 17: 449-454.
17. Thomas SL, De Vries GH (2007) Angiogenic expression profile of normal and neurofibromin-deficient human Schwann cells. Neurochem Res 32: 1129- 1141.
18. Yang FC, Chen S, Clegg T, Li X, Morgan T, et al. (2006) Nf1+/2 mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 15: 2421-2437.
19. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478. 4q12 Amplicon in MPNST PLoS ONE www.plosone.org 9 July 2010 Volume 5 Issue 7 e11858
20. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605.
21. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337.
22. Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, et al. (2007) MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9: 671-677.
23. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70: 1568-1578.
24. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, et al. (2009) Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 27: 3148-3153.
25. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, et al. (2008) Nf1-dependent tumors require a microenvironment containing Nf1+/2 and c-kit-dependent bone marrow. Cell 135: 437-448.
26. Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14: 207-221.
27. Sher I, Adham SA, Petrik J, Coomber BL (2009) Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124: 553-561.
28. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, et al. (2008) Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7: 2553-2561.
29. Angelov L, Salhia B, Roncari L, McMahon G, Guha A (1999) Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 59: 5536-5541.
30. Wasa J, Nishida Y, Suzuki Y, Tsukushi S, Shido Y, et al. (2008) Differential expression of angiogenic factors in peripheral nerve sheath tumors. Clin Exp Metastasis 25: 819-825.
31. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, et al. (2009) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol.